Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Kamaz will launch unmanned trucking along the M11 Neva highway in June

2/15/23 KMAZ

The Kraft Heinz announced a quarterly dividend

2/15/23 KHC

Kraft Heinz profit for 2022 increased 2.3 times

2/15/23 KHC

Biogen reported for year 2022

2/15/23 BIIB

TGC-14's profit according to RAS in 2022 increased 2.4 times

2/15/23 TGKN

VKontakte launched a new office for payment of income from content monetization

2/15/23 VKCO

GMV Yandex.Market in 2022 increased by 92%

2/15/23 YNDX

Yandex revenue in 2022 increased by 46.5%

2/15/23 YNDX

VK begins development of a game engine

2/15/23 VKCO

Ozon opened a Fulfillment Center in Kazakhstan

2/15/23 OZON